Microvasculopathic neuromuscular diseases: Lessons from hypoxia-inducible factors

Neuromuscular Disorders

Volumn 20, Issue 3, 2010, Pages 192-197

  Probst Cousin, Stefan ^a   Neundörfer, Bernhard ^b   Heuss, Dieter ^b  

^a KLINIKUM BREMEN OST   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Dermatomyositis; Hypoxia inducible factors; Vasculitic neuropathy; Vasculitis

Indexed keywords

ERYTHROPOIETIN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; DIABETIC NEUROPATHY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; INCLUSION BODY MYOSITIS; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC POLYANGIITIS; MUSCLE BLOOD FLOW; POLYARTERITIS NODOSA; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKELETAL MUSCLE; WEGENER GRANULOMATOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INDUCING AGENTS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; EPHRIN-B2; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MALE; MICROVESSELS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NEUROMUSCULAR DISEASES; PROTEINS; RECEPTORS, ERYTHROPOIETIN; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77950519057     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2010.01.005     Document Type: Article

References (54)

1. Hohlfeld R. Dysimmune myopathies. Definition of entities and experimental models of myositis. Structural and molecular basis of skeletal muscle diseases 2002, 218-220. ISN Neuropath Press, Basel. G. Karpati (Ed.).
2. Hohlfeld R. Polymyositis and dermatomyositis. Structural and molecular basis of skeletal muscle diseases 2002, 221-227. ISN Neuropath Press, Basel. G. Karpati (Ed.).
3. Limaye V.S., Blumbergs P., Roberts-Thomson P.J. Idiopathic inflammatory myopathies. Intern. Med. J. 2009, 39:179-190.
4. Collins M.P., Mendell J.R., Periquet M.I., et al. Superficial peroneal nerve/peroneus brevis muscle biopsy in vasculitic neuropathy. Neurology 2000, 55:636-643.
5. Engelhard A., Lörler H., Neundörfer B. Immunohistochemical findings in vasculitic neuropathies. Acta Neurol. Scand. 1993, 87:318-321.
6. Kissel J.T., Riethmann J.L., Omerza J. Peripheral nerve vasculitis: immune characterization of the vascular lesions. Ann. Neurol. 1989, 25:291-297.
7. Cupps T.R., Fauci A.S. The vasculitides. Major Probl. Intern. Med. 1981, 21:1-211.
8. Jennette J.C., Falk R.J., Andrassy K., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994, 37:187-192.
9. Carpenter S, Karpati G. Inflammatory myopathies. In: Carpenter S, Karpati G editors. Pathology of skeletal muscle. 2nd ed., Oxford: Oxford University Press; 2001. p. 542-543.
10. Kernohan J.W., Woltman H.W. Periarteritis nodosa. A clinicopathologic study with special reference to the nervous system. Arch. Neurol. Psych. 1938, 39:655-686.
11. Midroni G., Bilbao J.M. Vasculitic neuropathy. Biopsy diagnosis of peripheral neuropathy 1995, 241-262. Butterworth-Heinemann, Boston. G. Midroni, J.M. Bilbao (Eds.).
12. Heuss D., Probst-Cousin S., Kaiser C., Neundörfer B. Cell death in vasculitic neuropathy. Muscle Nerve 2000, 23:999-1004.
13. Satoi H., Oka N., Kawasaki T., Miyamoto K., Akiguchi I., Kimura J. Mechanisms of tissue injury in vasculitic neuropathies. Neurology 1998, 50:492-496.
14. 2 tension. Proc. Natl. Acad. Sci. USA 1995, 92:5510-5514.
15. Hofer T., Wenger R.H., Gassmann M. Oxygen sensing, HIF-1α stabilization and potential therapeutic strategies. Pflügers Arch. Eur. J. Physiol. 2002, 443:503-507.
16. Gassmann M., Wenger R.H. HIF-1, a mediator of the molecular response to hypoxia. News Physiol. Sci. 1997, 12:214-218.
17. Rosengart T.K., Lee L.Y., Patel S.R., et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999, 100:468-474.
18. Kikuchi K., Kubo M., Kadono T., Yazawa N., Ihn H., Tamaki K. Serum concentrations of vascular endothelial growth factor in collagen diseases. Br. J. Dermatol. 1998, 139:1049-1051.
19. Dalakas M.C., Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003, 362:971-982.
20. Dalakas M.C. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr. Opin. Neurol. 2004, 17:561-567.
21. Lee S.H., Wolf P.L., Escudero R., Deutsch R., Jamieson S.W., Thistlethwaite P.A. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N. Engl. J. Med. 2000, 342:626-633.
22. Rissanen T.T., Vajanto I., Hiltunen M.O., et al. Expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 (KDR/Flk-1) in ischemic skeletal muscle and its regeneration. Am. J. Pathol. 2002, 160:1393-1403.
23. Stroka D.M., Burkhardt T., Desbaillets I., et al. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J. 2001, 15:2445-2453.
24. Oka N., Kawasaki T., Mitzutani K., Sugiyama H., Akiguchi I. Hypoxia-inducible factor 1α may be a marker for vasculitic neuropathy. Neuropathology 2009, 27:509-515.
25. Wang G.L., Semenza G.L. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc. Natl. Acad. Sci. USA 1993, 90:4304-4308.
26. Konttinen Y.T., Mackiewicz Z., Povilenaite D., Sukura A., Hukkanen M., Virtanen I. Disease-associated increased HIF-1, avβ3 integrin, and Flt-1 do not suffice to compensate the damage-inducing loss of blood vessels in inflammatory myopathies. Rheumatol. Int. 2004, 24:333-339.
27. Tian H., McKnight S.L., Russel D.W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 1997, 11:72-82.
28. Wiesener M.S., Jürgensen J.S., Rosenberger C., et al. Widespread, hypoxia-inducible expression of HIF-2α in distinct cell populations of different organs. FASEB J. 2003, 17:271-273.
29. Grange R.W., Meeson A., Chin E., et al. Functional and molecular adaptations in skeletal muscle of myoglobin-mutant mice. Am. J. Physiol. Cell Physiol. 2001, 281:C1487-1494.
30. Kappel A., Rönicke V., Damert A., Flamme I., Risau W., Breier G. Identification of vascular endothelial growth factor (VEGF) receptor-2 (Flk-1) promoter/enhancer sequences sufficient for angioblast and endothelial cell-specific transcription in transgenic mice. Blood 1999, 93:4284-4292.
31. O'Rourke J.F., Tian Y.M., Ratcliffe P.J., Pugh C.W. Oxygen-regulated and transactivating domains in endothelial PAS protein 1: comparison with hypoxia-inducible factor 1α. J. Biol. Chem. 1999, 274:2060-2071.
32. Ema M., Taya S., Yokotani N., Sogawa K., Matsuda Y., Fuji-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl. Acad. Sci. USA 1997, 94:4273-4278.
33. Forsythe J.A., Jiang B.H., Iyer N.V., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 1996, 16:4604-4613.
34. Shima D.T., Kuroki M., Deutsch U., Ng Y.S., Adamis A.P., D'Amore P.A. The mouse gene for vascular endothelial growth factor: genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J. Biol. Chem. 1996, 271:3877-3883.
35. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999, 13:9-22.
36. Kalka C., Masuda H., Takahashi T., et al. Vascular endothelial growth factor (165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ. Res. 2000, 86:1198-1202.
37. Grundtman C., Tham E., Ulfgren A.K., Lundberg I.E. Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis. Arthritis Rheum. 2008, 58:3224-3238.
38. Fisher J.W. Erythropoietin: physiology and pharmacology update. Exp. Biol. Med. 2003, 228:1-14.
39. Yasuda Y., Fulita Y., Musha T., et al. Expression of erythropoietin in human female reproductive organs. Ital. J. Anat. Embryol. 2001, 106:215-222.
40. Junk A.K., Mammis A., Savitz S.I., et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc. Natl. Acad. Sci. USA 2002, 99:10659-10664.
41. Juul S. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr. Suppl. 2002, 91:36-42.
42. Augustin H.G. Angiogenesis research - Quo vadis? (in German). Ophthalmologe 2003, 100:104-110.
43. Hoke A., Sun H.S., Gordon T., Zochodne D.W. Do denervated peripheral nerve trunks become ischemic? The impact of chronic denervation on vasa nervorum. Exp. Neurol. 2001, 172:398-406.
44. Schratzberger P., Schratzberger G., Silver M., et al. Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat. Med. 2000, 6:405-413.
45. Cherwek D.H., Hopkins M.B., Thompson M.J., Annex B.H., Taylor D.A. Fiber type-specific differential expression of angiogenic factors in response to chronic hindlimb ischemia. Am. J. Physiol. Heart Circ. Physiol. 2000, 279:932-938.
46. Gustafsson T., Knutsson A., Puntschart A., et al. Increased expression of vascular endothelial growth factor in human skeletal muscle in response to short-term one-legged exercise training. Pflügers Arch. 2003, 444:752-759.
47. Gustafsson T., Puntschart A., Kaijser L., Jansson E., Sundberg C.J. Exercise-induced expression of angiogenesis-related transcription and growth factors in human skeletal muscle. Am. J. Physiol. Heart Circ. Physiol. 1999, 45:H679-H685.
48. Wagner P.D. Skeletal muscle angiogenesis. A possible role for hypoxia. Adv. Exp. Med. Biol. 2001, 502:21-38.
49. Nagaraju K., Rider L.G., Fan C., et al. Endothelial cell activation and neovascularization are prominent in dermatomyositis. J. Autoimmune Dis. 2006, 3:2.
50. Carvalho J.F., Blank M., Shoenfeld Y. Vascular endothelial growth factor (VEGF) in autoimmune diseases. J. Clin. Immunol. 2007, 27:246-256.
51. Springer M.L., Chen A.S., Kraft P.E., Bednarski M., Blau H.M. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol. Cell. 1998, 2:549-558.
52. Khan T.A., Sellke F.W., Laham R.J. Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia. Gene Ther. 2003, 10:285-291.
53. Greenberg S.A. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007, 69:2008-2019.
54. Hohlfeld R., Dornmair K. Revisiting the immunopathogenesis of the inflammatory myopathies. Neurology 2007, 69:1966-1967.